nasopharyngeal-carcinoma

Documents about nasopharyngeal-carcinoma

• Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer#279520ClinicalTrials.gov
• Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer#876461ClinicalTrials.gov
• Nimotuzumab for Recurrent Nasopharyngeal Carcinoma#892156ClinicalTrials.gov
• Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer#28329ClinicalTrials.gov
• Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma#894715ClinicalTrials.gov
• Immune Score Based Radiomics in Nasopharyngeal Carcinoma#890605ClinicalTrials.gov
• Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma#916010ClinicalTrials.gov
• Cadonilimab (PD-1/CTLA-4 Bispecific Blockade) and Chemoradiotherapy in Nasopharyngeal Carcinoma (GEMSTONE)#429752ClinicalTrials.gov
• Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma#245487ClinicalTrials.gov
• Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma#886438ClinicalTrials.gov
• Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma#373615ClinicalTrials.gov
• A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal Carcinoma#478239ClinicalTrials.gov
• Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma#902841ClinicalTrials.gov
• Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy#885897ClinicalTrials.gov
• Long-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone#902067ClinicalTrials.gov
• Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma#160338ClinicalTrials.gov
• Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma#807751ClinicalTrials.gov
• Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma#905742ClinicalTrials.gov
• Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)#674906ClinicalTrials.gov
• Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma#184862ClinicalTrials.gov
• Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma#414500ClinicalTrials.gov
• Intermittent Oral-esophageal Tube in Delayed Dysphagia After Radiotherapy for Nasopharyngeal Carcinoma#899602ClinicalTrials.gov
• Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial#279488ClinicalTrials.gov
• Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy#805754ClinicalTrials.gov
• Adaptive Immunotherapy for Nasopharyngeal Carcinoma#143543ClinicalTrials.gov
• SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.#852393ClinicalTrials.gov
• Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma#837285ClinicalTrials.gov
• Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal Carcinoma#849612ClinicalTrials.gov
• OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy#1031642ClinicalTrials.gov
• 18F-FMISO PET Guided Dose Escalation in Nasopharyngeal Carcinoma - a Feasibility and Planning Study#874337ClinicalTrials.gov
• Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma#195322ClinicalTrials.gov
• PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma#261516ClinicalTrials.gov
• Functional Electrical Stimulation in Irradiated Nasopharyngeal Carcinoma (NPC)#828727ClinicalTrials.gov
• Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma#828926ClinicalTrials.gov
• Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma#898853ClinicalTrials.gov
• Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma#910946ClinicalTrials.gov
• Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma#980727ClinicalTrials.gov
• Nivolumab in Children and Adults With Nasopharyngeal Carcinoma#893983ClinicalTrials.gov
• Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.#881713ClinicalTrials.gov
• Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma#377417ClinicalTrials.gov
• Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma#838862ClinicalTrials.gov
• The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma#858705ClinicalTrials.gov
• Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma#873997ClinicalTrials.gov
• Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma#899376ClinicalTrials.gov
• Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma#810814ClinicalTrials.gov
• Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.#855351ClinicalTrials.gov
• EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma#804858ClinicalTrials.gov
• A Multicenter, Prospective, Phase III Clinical Study of Proton Intensity-modulated Radiotherapy Versus Photon Intensity-modulated Radiotherapy for Untreated Non-metastatic Nasopharyngeal Carcinoma#895537ClinicalTrials.gov
• Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma#912545ClinicalTrials.gov
• Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s)#843470ClinicalTrials.gov